Baltimore Capital Management’s Amgen AMGN Stock Holding History

Baltimore Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,250	Closed	-$205K	–	70
2017 Q1	$205K	Buy	+1,250	New	+$208K	0.27%	65

Other funds holding AMGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baltimore Capital Management's AMGN Position: Q2 2017 in Review

Baltimore Capital Management sold out of Amgen (AMGN) in Q2 2017, closing a stake of 1,250 shares — an estimated $205K sold.

Baltimore Capital Management first reported a position in AMGN in Q1 2017 and held it in 1 quarter. The position peaked at $205K in Q1 2017. 1,595 funds tracked by Wall St. Rank hold AMGN as of Q2 2017.

Baltimore Capital Management reported no remaining Amgen position as of Q2 2017 after selling out during the quarter.
Baltimore Capital Management sold 1,250 Amgen shares in Q2 2017, an estimated $205K.
Baltimore Capital Management first reported a position in Amgen in Q1 2017 and held it in 1 quarter.
Baltimore Capital Management's Amgen position peaked at $205K in Q1 2017.
1,595 funds tracked by Wall St. Rank held Amgen as of Q2 2017.

Based on Baltimore Capital Management's 13F filing for Q2 2017, filed 9 Aug 2017.